"10.1371_journal.pone.0093986","plos one","2014-04-04T00:00:00Z","Thomas Stig Hermansen; Vibeke Østergaard Thomsen; Troels Lillebaek; Pernille Ravn","Department of Thoracic Medicine and Infectious Disease, Nordsjaelland Hospital, Hillerød, Denmark; International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark","Conceived and designed the experiments: TSH PR VOT. Performed the experiments: TSH TL VOT PR. Analyzed the data: TSH PR. Contributed reagents/materials/analysis tools: TL VOT. Wrote the paper: TSH PR VOT TL.","The authors have the following interests. Thomas Stig Hermansen (TSH), Vibeke Østergaard Thomsen (VOT), and Troels Lillebaek (TL) are working at Statens Serum Institut in a department that analyses QuantiFERON tests from parts of Denmark. Pernille Ravn (PR) states: Hvidovre Hospital has filed a patent on the use of IP-10 as a marker for infection with mycobacterium tuberculosis, and PR is one of the registered co-inventors. PR has been an invited speaker by Cellestis and has received QFT-IT kits at a reduced price for non profit research. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. Last author Pernille Ravn has provided supplementary information on the patents regarding the biomarker IP-10 and states: “Copenhagen University Hospitals, Hvidovre, hold the following pending and issued patents disclosing the use of IP-10 as a diagnostic marker for infection with M. tuberculosis: WO2011137902 (filed 04.05.2010), WO2007DK00399 (filed 05.09.2007).” Pernille Ravn is registered as one of the inventors. This does not alter her adherence to PLOS ONE policies on sharing data and materials.","2014","04","Thomas Stig Hermansen","TSH",4,TRUE,3,4,2,4,TRUE,TRUE,TRUE,1,"2",FALSE
